New York State Teachers Retirement System Increases Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)

New York State Teachers Retirement System grew its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 3.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 128,232 shares of the biotechnology company’s stock after acquiring an additional 3,789 shares during the quarter. New York State Teachers Retirement System’s holdings in Corcept Therapeutics were worth $6,462,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Creative Planning boosted its position in shares of Corcept Therapeutics by 7.2% in the 3rd quarter. Creative Planning now owns 12,467 shares of the biotechnology company’s stock worth $577,000 after purchasing an additional 841 shares in the last quarter. Blue Trust Inc. lifted its position in Corcept Therapeutics by 230.6% during the 3rd quarter. Blue Trust Inc. now owns 11,658 shares of the biotechnology company’s stock worth $540,000 after acquiring an additional 8,132 shares during the period. Allspring Global Investments Holdings LLC lifted its position in Corcept Therapeutics by 97.2% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 251,068 shares of the biotechnology company’s stock worth $11,619,000 after acquiring an additional 123,720 shares during the period. Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Corcept Therapeutics by 16.5% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 69,327 shares of the biotechnology company’s stock valued at $3,208,000 after buying an additional 9,838 shares during the period. Finally, Wealth Enhancement Advisory Services LLC acquired a new position in shares of Corcept Therapeutics in the 3rd quarter valued at about $238,000. 93.61% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the company’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $68.08, for a total transaction of $149,776.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Joseph Douglas Lyon sold 1,411 shares of the company’s stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $56.72, for a total value of $80,031.92. Following the sale, the insider now directly owns 8,494 shares in the company, valued at $481,779.68. This represents a 14.25 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 28,011 shares of company stock worth $1,479,608 over the last ninety days. Corporate insiders own 20.50% of the company’s stock.

Corcept Therapeutics Trading Up 1.3 %

CORT opened at $73.53 on Thursday. Corcept Therapeutics Incorporated has a one year low of $20.84 and a one year high of $75.00. The stock has a market capitalization of $7.70 billion, a PE ratio of 58.36 and a beta of 0.58. The business’s 50 day moving average price is $58.79 and its 200 day moving average price is $50.15. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.70.

Analyst Upgrades and Downgrades

CORT has been the subject of several recent analyst reports. Canaccord Genuity Group lifted their price target on Corcept Therapeutics from $78.00 to $130.00 and gave the company a “buy” rating in a research note on Thursday, January 30th. HC Wainwright reiterated a “buy” rating and set a $80.00 price objective on shares of Corcept Therapeutics in a research note on Friday, February 7th. Finally, StockNews.com cut Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday, November 25th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Corcept Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $88.25.

Corcept Therapeutics Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.